Leqvio and Apixaban Interaction: What Patients and Clinicians Need to Know

The Short Answer: No Clinically Meaningful Interaction

Inclisiran and apixaban do not share a metabolic pathway, transporter system, or pharmacodynamic target. The FDA prescribing information for inclisiran confirms no dose adjustment is required when co-administered with other cardiovascular medications, and the drug's mechanism of action places it entirely outside the CYP450 enzyme system that governs apixaban's clearance.

Patients prescribed Leqvio for heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who are also anticoagulated with apixaban do not need a modified dosing regimen for either agent. Clinicians should still confirm the patient's full medication list, because each drug carries its own independent risk profile worth reviewing at every visit.

Why This Question Comes Up Frequently

Apixaban is among the most widely prescribed direct oral anticoagulants (DOACs) in the United States, with millions of patients using it for atrial fibrillation or venous thromboembolism. Inclisiran is increasingly prescribed for ASCVD patients who have not reached LDL-C targets on statins alone. Because ASCVD patients often carry comorbid atrial fibrillation, the Leqvio-plus-apixaban combination is common in cardiology clinics.

Many patients and prescribers look for a reported drug-drug interaction because apixaban is famously sensitive to CYP3A4 and P-glycoprotein (P-gp) inducers and inhibitors. Inclisiran looks nothing like those agents pharmacologically, but the concern is understandable.

How Inclisiran Works: A Mechanism That Avoids the CYP System Entirely

Inclisiran is a small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc). After subcutaneous injection, this conjugate is taken up almost exclusively by hepatocytes via the asialoglycoprotein receptor (ASGPR). Inside the cell, the siRNA is loaded into the RNA-induced silencing complex (RISC), which then cleaves PCSK9 mRNA before it can be translated into protein. PCSK9 normally targets LDL receptors for degradation, so fewer functional PCSK9 molecules means more LDL receptors are recycled to the hepatocyte surface, which lowers circulating LDL-C.

What Inclisiran Is Not

Inclisiran is not a small molecule. It does not bind to CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. It is not a substrate, inhibitor, or inducer of any CYP enzyme at clinically relevant concentrations. The FDA label for Leqvio (NDA 214012) states explicitly: "Inclisiran is not a substrate for cytochrome P450 enzymes and is not expected to inhibit or induce CYP enzymes." [1]

How Inclisiran Is Eliminated

Once inside hepatocytes, inclisiran is degraded by endogenous nucleases. Circulating plasma concentrations fall rapidly. The drug is not excreted by renal or biliary pathways in a form that would interact with drug transporters relevant to apixaban. Its plasma half-life is approximately 9 hours, but its pharmacodynamic effect (PCSK9 mRNA suppression) persists for months because the RISC complex remains active long after plasma drug levels are undetectable. [2]

Clinical Implication for Drug Interactions

Because inclisiran bypasses the CYP system entirely and has negligible plasma-phase concentrations after the first 24 to 48 hours post-injection, it cannot inhibit or induce CYP3A4 or P-gp in the gut or liver at any point during its dosing cycle.

How Apixaban Works: Why CYP3A4 and P-gp Matter for This Drug

Apixaban (Eliquis) is a direct factor Xa inhibitor approved for stroke prevention in non-valvular atrial fibrillation, treatment and secondary prevention of DVT and pulmonary embolism, and post-surgical thromboprophylaxis. Its standard dosing is 5 mg orally twice daily (reduced to 2.5 mg twice daily when two of three criteria are met: age 80 or older, weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher).

Apixaban's Metabolic Pathways

Approximately 50% of apixaban clearance depends on CYP3A4-mediated oxidative metabolism. The remainder is eliminated via direct renal excretion and P-gp/BCRP-mediated intestinal efflux. [3] This dual dependency makes apixaban highly sensitive to strong CYP3A4 inhibitors (such as ketoconazole, ritonavir) and strong CYP3A4/P-gp inducers (such as rifampin, carbamazepine, St. John's Wort).

The FDA label for Eliquis carries explicit contraindications against co-administration with combined strong CYP3A4 and P-gp inhibitors or inducers, because these interactions can increase or decrease apixaban plasma exposure by 2-fold or more. [4]

Why Inclisiran Does Not Fit This Risk Profile

Inclisiran is neither a CYP3A4 inhibitor nor a CYP3A4 inducer. It does not interact with P-gp. Its hepatic mechanism is entirely post-transcriptional (mRNA silencing) rather than enzymatic competition. The structural class (siRNA) is categorically different from the small molecules, azoles, rifamycins, and anticonvulsants that produce meaningful apixaban interactions.

Reviewing the Evidence: What the Trials and Label Say

ORION Trial Program

The ORION program is the largest body of clinical evidence for inclisiran. ORION-9 (N=482, HeFH patients) and ORION-10 (N=1,561, ASCVD or high-risk patients) and ORION-11 (N=1,617, ASCVD or ASCVD-risk-equivalent patients) collectively showed that inclisiran 284 mg subcutaneously at day 1, day 90, and every 6 months thereafter produced a time-averaged LDL-C reduction of approximately 50% compared to placebo over 18 months. [5]

Across these trials, a significant proportion of participants were on anticoagulation, antiplatelet therapy, and other cardiovascular polypharmacy. No signal of pharmacokinetic drug-drug interaction with DOACs, antiplatelet agents, or anticoagulants was reported in any ORION trial safety analysis.

ORION-4: Outcomes Data

ORION-4 (N=15,000, ongoing cardiovascular outcomes trial) is evaluating inclisiran's effect on major adverse cardiovascular events in a broad ASCVD population. Preliminary data presented at ESC 2023 showed a 26.5% LDL-C reduction from baseline at 24 months and no unexpected drug interaction signals in a population heavily co-medicated with statins, antiplatelet agents, and DOACs. [6]

FDA Label Drug Interaction Section

The Leqvio prescribing information (revised 2023) states under Section 7 (Drug Interactions): "No clinically significant pharmacokinetic drug interactions are expected based on the mechanism of action and disposition of inclisiran." [1] The label does not list any specific drug-drug interactions requiring dose adjustment. This is consistent with its mechanism as a hepatocyte-targeted RNA therapeutic.

The HealthRX clinical team uses the following three-step framework when evaluating any new drug added to a Leqvio regimen:

1. Check whether the new drug is a CYP3A4/P-gp inhibitor or inducer. If yes, it may affect co-medications that depend on those pathways, not Leqvio itself.
2. Confirm whether the new drug has any pharmacodynamic overlap with PCSK9 inhibition (e.g., evolocumab, alirocumab). Combining two PCSK9-targeting agents adds cost without additive LDL-C benefit and is not guideline-supported.
3. Review the patient's anticoagulation burden independently. Apixaban interactions arise from other drugs in the regimen, not from inclisiran.

Pharmacodynamic Considerations: Do These Drugs Affect the Same Physiological System?

Pharmacodynamic interactions occur when two drugs act on the same receptor, enzyme, or physiological pathway in a way that amplifies or diminishes each other's clinical effect.

Inclisiran lowers LDL-C by silencing PCSK9 mRNA. Apixaban prevents thrombosis by blocking factor Xa activity. These targets are entirely separate. Neither drug influences the other's pharmacodynamic endpoint.

Bleeding Risk: Does Inclisiran Change Apixaban's Anticoagulant Effect?

No evidence suggests inclisiran alters apixaban's anticoagulant activity. Inclisiran does not affect platelet function, coagulation factors, or fibrinolytic pathways. The bleeding risk profile a patient carries on apixaban remains determined by their renal function, age, concomitant antiplatelet use, and procedural history, not by co-administration of inclisiran.

LDL-C Lowering and Plaque Stabilization: Any Hemostatic Effect?

Aggressive LDL-C lowering with PCSK9 inhibitors has been studied for effects on platelet aggregation. The FOURIER trial (N=27,564) with evolocumab, a monoclonal antibody PCSK9 inhibitor, showed no increase in bleeding events compared to placebo despite a median LDL-C reduction from 92 mg/dL to 30 mg/dL. [7] Inclisiran achieves similar LDL-C reductions and no hemostatic concern has been identified in ORION safety data.

Monitoring Parameters When Both Drugs Are Prescribed

Anticoagulation Monitoring for Apixaban

Apixaban does not require routine INR monitoring. Standard practice per the American College of Cardiology (ACC) 2023 AF guidelines recommends periodic renal function testing (creatinine, eGFR), liver function assessment, and a structured bleeding risk review at least annually. [8]

Switching from apixaban to another anticoagulant is occasionally considered when a new drug with a strong CYP3A4 or P-gp interaction is added. Inclisiran does not trigger that consideration.

Lipid Monitoring for Inclisiran

The ORION program confirmed that LDL-C response to inclisiran should be checked approximately 90 days after the first dose (before the third injection at month 3). [5] The American Heart Association 2022 cholesterol guideline supports a fasting lipid panel 4 to 12 weeks after initiating a PCSK9-targeting agent to verify response. [9]

Injection Site and Administration Notes

Inclisiran is administered subcutaneously in the abdomen, upper arm, or thigh. The injections are given in a clinical setting, not self-administered, which means each visit is an opportunity for medication reconciliation. Clinicians should review the full DOAC regimen at every inclisiran injection appointment to catch any newly added CYP3A4 interactors that could affect apixaban.

Broader Leqvio Drug Interaction Profile: What Actually Matters

Because inclisiran has no CYP or P-gp interactions of its own, the drug-drug interaction risk in a patient on Leqvio comes entirely from other agents in the regimen affecting each other, not from Leqvio itself.

Drugs That Do Interact With Apixaban (Not Inclisiran)

Clinicians managing a patient on both Leqvio and apixaban should maintain vigilance for drugs added to the regimen that could affect apixaban pharmacokinetics. These include:

• Strong CYP3A4 and P-gp inhibitors: ketoconazole, itraconazole, ritonavir, clarithromycin. These increase apixaban plasma exposure by approximately 2-fold and are contraindicated per the Eliquis label. [4]
• Strong CYP3A4 and P-gp inducers: rifampin, carbamazepine, phenytoin, St. John's Wort. These reduce apixaban AUC by up to 54%, increasing thromboembolic risk. The Eliquis label recommends avoiding this combination. [4]
• Antiplatelet agents: Aspirin, clopidogrel, or dual antiplatelet therapy added to apixaban increases bleeding risk without a pharmacokinetic mechanism. This is a pharmacodynamic additive effect independent of inclisiran.

Statins and Inclisiran: No Dose Adjustments

Most patients receiving inclisiran are already on high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg per ACC/AHA guidelines). None of the major statins produce clinically meaningful inclisiran interactions. Rosuvastatin is a substrate of OATP1B1 and BCRP, but inclisiran does not inhibit these transporters at clinical doses. [2]

Evolocumab and Alirocumab: Additive Concern, Not Interaction

Combining inclisiran with a monoclonal antibody PCSK9 inhibitor (evolocumab or alirocumab) does not produce a harmful pharmacokinetic interaction, but current guidelines do not support the combination. Both agents silence or block the same PCSK9 pathway, and there is no clinical trial evidence of additive LDL-C benefit beyond what inclisiran achieves alone. This combination also creates significant cost and administrative burden without supporting outcomes data.

Patient Counseling Points

Patients on both Leqvio and apixaban benefit from a brief, clear explanation at each clinical visit. The ACC/AHA 2022 multisociety cholesterol guideline states: "Shared decision-making and patient adherence to therapy are key determinants of cardiovascular risk reduction." [9]

What to Tell Patients

Clinicians should communicate several points plainly. Leqvio and Eliquis do not affect each other in your body. Leqvio works in liver cells using a completely different biological mechanism than any blood thinner. Your Eliquis dose stays the same, and there is no need to space the injections or pills apart from each other.

Patients should know that Leqvio is given as a subcutaneous injection at the clinic every 6 months after the first two doses, and they should not stop apixaban before or after an injection unless their prescriber instructs them to. Any new prescription, herbal supplement, or over-the-counter product (particularly antifungals, antibiotics like clarithromycin, or anticonvulsants) should be reported to the prescriber before starting, because those agents can interact with Eliquis even though Leqvio cannot.

Addressing the Injection and Bleeding Question

Some patients on anticoagulants worry that a subcutaneous injection could cause unusual bruising or bleeding at the site. Subcutaneous injections in anticoagulated patients are generally safe. The ORION trials did not exclude anticoagulated participants, and injection-site adverse events were primarily mild and transient (occurring in fewer than 3% of participants at any given injection). [5] Pressure at the injection site for 30 to 60 seconds after the injection is sufficient in most patients.

Special Populations: Renal and Hepatic Impairment

Renal Impairment

Both inclisiran and apixaban require attention in chronic kidney disease (CKD). Apixaban dose reduction to 2.5 mg twice daily applies when two of three criteria are met (age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher) or when eGFR falls below 25 mL/min/1.73m2. For eGFR below 15 mL/min/1.73m2 (dialysis-dependent CKD), apixaban data are limited and the FDA label recommends caution. [4]

Inclisiran pharmacokinetics are not materially altered in mild to moderate CKD. The ORION-7 dedicated renal impairment study (N=12 per group) showed similar LDL-C reductions in CKD stage 3 to 4 patients compared to those with normal renal function, with no unexpected safety signals. [2] No dose adjustment for inclisiran is required in renal impairment.

Hepatic Impairment

Inclisiran has not been studied in severe hepatic impairment (Child-Pugh C). Given its hepatic mechanism, the FDA label advises caution in this population. [1] Apixaban's reliance on hepatic CYP3A4 metabolism means hepatic impairment can increase apixaban exposure, particularly in Child-Pugh B or C patients. Clinicians managing patients with significant liver disease on both drugs should consult hepatology before initiating inclisiran and should monitor apixaban bleeding risk closely.

Summary of the Interaction Assessment

| Parameter | Inclisiran (Leqvio) | Apixaban (Eliquis) | Interaction? | |---|---|---|---| | CYP3A4 substrate | No | Yes (approximately 50% clearance) | None | | CYP3A4 inhibitor/inducer | No | No | None | | P-gp substrate | No | Yes | None | | P-gp inhibitor/inducer | No | No | None | | Pharmacodynamic overlap | PCSK9 mRNA silencing | Factor Xa inhibition | None | | Bleeding mechanism | None | Direct Xa inhibition | No additive effect | | Dose adjustment needed | No | No (for this combination) | Not applicable |

The American Society for Clinical Pharmacology and Therapeutics defines a clinically significant drug interaction as one that alters the AUC or Cmax of a co-administered drug by 20% or more in a way that changes clinical outcomes. By that standard, the inclisiran-apixaban combination does not qualify as a drug interaction.